公告显示，聚药堂是一家专注于中药饮片、毒性中药饮片、直接口服中药饮片及配方颗粒生产销售的企 业，具有持续稳定的盈利能力。 北京商报讯（记者 丁宁）8月15日晚间，云南白药（000538）发布公告称，为响应云南省人民政府提出 的高质量发展云南省中药材产业的要求，结合公司自身战略发展目标，为更好带动云南省内中药材销 售，更快推动云南白药相关业务布局全国，实现规模扩张，提升中药材产业链协同效率，公司全资子公 司云南白药集团中药资源有限公司将以现金方式收购安国市聚药堂药业有限公司（以下简称"聚药堂"） 100%股权，股权转让对价总额为6.6亿元。 ...

Group 1 - The company announced that its wholly-owned subsidiary, Yunnan Baiyao Group Traditional Chinese Medicine Resources Co., Ltd., plans to acquire 100% equity of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million yuan in cash [1] - The acquisition aims to respond to the high-quality development requirements of the traditional Chinese medicine industry in Yunnan Province and align with the company's strategic development goals [1] - The acquisition is expected to enhance the sales of traditional Chinese medicine materials within Yunnan Province, accelerate the national business layout of Yunnan Baiyao, achieve scale expansion, and improve the collaborative efficiency of the traditional Chinese medicine industry chain [1] Group 2 - Ju Yao Tang specializes in the production and sales of traditional Chinese medicine pieces, toxic traditional Chinese medicine pieces, directly consumable traditional Chinese medicine pieces, and formula granules, demonstrating stable and sustainable profitability [1]